PharmiNews

The Directory of Pharma Companies and News

Gilead

Gilead logo
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
Category: Biotech
Category: Biotech

Gilead News

DateNews
2017-08-01U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in P...
2017-07-28European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the...
2017-07-26Gilead Sciences Announces Third Quarter 2017 Dividend
2017-07-26Gilead Sciences Announces Second Quarter 2017 Financial Results
2017-07-24Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir ...
2017-07-18U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment o...
2017-07-13European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Bictegravir, Emtricit...
2017-07-12Gilead Sciences to Release Second Quarter 2017 Financial Results on Wednesday, July 26, 2017
2017-06-23European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of...
2017-06-12Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtr...
2017-06-01Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
2017-05-30Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
2017-05-30Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatm...
2017-05-04Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
2017-05-02Gilead Sciences Announces Second Quarter 2017 Dividend
2017-05-02Gilead Sciences Announces First Quarter 2017 Financial Results
2017-04-21Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Cong...
2017-04-21Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient...
2017-04-20Gilead Presents Data at the International Liver Congressâ„¢ 2017 Supporting the Efficacy and Safety of Vemlidy in Patien...
2017-04-20Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congre...
2017-04-18Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
2017-04-07U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepa...
2017-02-28Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
2017-02-14Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Ad...
2017-02-13Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
2017-02-13Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatmen...
2017-02-08Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
2017-02-07Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
2017-02-07Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
2017-01-24Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
2017-01-20European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis...
2017-01-11European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatme...
2017-01-10Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
2017-01-03Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
2016-09-27Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
2016-09-21Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
2016-09-15Gilead Prices $5 Billion of Senior Unsecured Notes
2016-09-06Gilead Sciences to Present at Three Upcoming Investor Conferences in September
2016-08-23Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
2016-08-22European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually...
2016-07-25Gilead Sciences Announces Third Quarter 2016 Dividend
2016-07-25Gilead Sciences Announces Second Quarter 2016 Financial Results
2016-07-22European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of...
2016-07-21Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b...
2016-07-18Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
2016-07-08European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment o...
2016-06-28U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genoty...
2016-06-23European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpiv...
2016-06-20Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatmen...
2016-06-13Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
2016-06-09Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
2016-06-07Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
2016-05-27European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotyp...
2016-05-24Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Execut...
2016-05-20Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
2016-05-09Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10
2016-04-29European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpiviri...
2016-04-28Gilead Sciences Announces Second Quarter 2016 Dividend
2016-04-28Gilead Sciences Announces First Quarter 2016 Financial Results
2016-04-25European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenof...
2016-04-21Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
2016-04-16Gilead Presents New Data Highlighting Progress in Liver Fibrosis
2016-04-16Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
2016-04-15Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With ...
2016-04-04Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other ...
2016-04-04U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based ...
2016-04-04Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) Program for NASH and Other ...
2016-03-31Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TA...
2016-03-10Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
2016-03-04Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
2016-03-04Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
2016-03-01U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, R...
2016-02-26European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenami...
2016-02-25European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment o...
2016-02-24Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
2016-02-23Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Reg...
2016-02-23Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
2016-02-22Gilead Launches New Grants Program to Support HIV Cure
2016-02-16U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
2016-02-08Gilead Sciences to Participate in Two Upcoming Investor Conferences
2016-02-02Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
2016-02-02Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results
2016-02-01European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexu...
2016-02-01Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
2016-01-29Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed ...
2016-01-26Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
2016-01-19Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib
2016-01-13Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
2016-01-12Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatme...
2016-01-08Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
2016-01-05Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chro...
2016-01-05Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
2016-01-04Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chron...
2015-12-17Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Oth...
2015-12-08Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented ...
2015-12-04European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvi...
2015-11-24Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1
2015-11-23European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicis...
2015-11-16Gilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase...
2015-11-14Gilead Presents New Data at The Liver Meeting 2015
2015-11-14Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis ...
2015-11-12U.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single Tablet Regimen for Chronic Hepatitis C
2015-11-09Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10
2015-11-05U.S. Food and Drug Administration Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtrici...
2015-10-28Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpat...
2015-10-27Gilead Sciences Announces Third Quarter 2015 Financial Results
2015-10-27Gilead Sciences Announces Fourth Quarter 2015 Dividend
2015-10-22Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an I...
2015-10-21Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
2015-10-20Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015
2015-10-02U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis® with Tadalafil for Pulmona...
2015-09-25European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricit...
2015-09-21Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SO...
2015-09-15Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16
2015-09-09Gilead Prices $10 Billion of Senior Unsecured Notes
2015-09-08Gilead Sciences to Present at the Baird 2015 Healthcare Conference on Wednesday, September 9
2015-09-02Gilead’s Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week O...
2015-08-26Results From the AMBITION Study of First-Line Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension P...
2015-08-20European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, E...
2015-07-28Gilead Sciences Announces Third Quarter 2015 Dividend
2015-07-28Gilead Sciences Announces Second Quarter 2015 Financial Results
2015-07-21Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regim...
2015-07-21Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015
2015-07-03Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Harvoni®, the First Once-Daily Single Tablet Regim...
2015-07-01Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Ri...
2015-06-08Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 9
2015-05-31Zydelig® in Combination With Ofatumumab Improves Progression-Free Survival in Previously-Treated Patients With Chronic ...
2015-05-28European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Ten...
2015-05-27Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
2015-05-18Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
2015-05-12Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13
2015-05-06Gilead Sciences Acquires EpiTherapeutics
2015-04-30Gilead Sciences Declares First Quarterly Cash Dividend
2015-04-30Gilead Sciences Announces First Quarter 2015 Financial Results
2015-04-25Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotype...
2015-04-23Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Di...
2015-04-23Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857...
2015-04-23Gilead Sciences to Release First Quarter 2015 Financial Results on Thursday, April 30, 2015
2015-04-07Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Ten...
2015-03-26Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotyp...
2015-03-10Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
2015-03-02Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
2015-02-26Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenami...
2015-02-26Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patient...
2015-02-25Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
2015-02-24Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25
2015-02-09Gilead Sciences to Present at Two Upcoming Investor Conferences
2015-02-03Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
2015-02-03Gilead Sciences Announces 43 Cents Quarterly Dividend Program and $15 Billion Share Buyback Program
2015-01-28Gilead Announces Executive Promotions
2015-01-27Gilead Sciences to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 3, 2015
2015-01-26Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent
2015-01-12Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
2015-01-06Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis...
1970-01-01Mundipharma calls for broader stakeholder consensus on pain trial endpoints to meet payer’s requirements (PDF)
1970-01-01Future doctors unprepared to manage pain - one of the most common problems they will encounter in clinical practice, exp... (PDF)
1970-01-01Data show asthma exacerbation rates remain high, even among patients meeting criteria for current clinical control (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.